Progressive EGFR/ALK NSCLC on third-generation TKI with 12 asymptomatic sub-cm BrMAll 4 scenarios where new TKI CNS RR > 50%, and mDOR ≥6 mo (CV 8b-e). This evidence concerns the gene ALK and non-small cell lung carcinoma.